Likewise, Ampio has yet to explain why the clear failure of a small study of its experimental drug Optina in diabetic macular edema was spun as a success.
A phase III study of Optina in diabetic macular edema is now underway, even though its design falls well short of what's necessary for FDA approval.
Ampio is happy to accuse short sellers of attacking the company but can't respond intelligently to criticisms about a subpar phase III Optina study.
As Dredly also points out correctly, Ampio has also missed or changed its guidance about the development of the osteoarthritis drug Ampion, without explanation. Why did the company change the primary endpoint of a phase II study conducted in Australia last year? Why did the company first claim to reach agreement with the FDA to begin phase III studies of Ampion but then concede the need for a phase II study?On these important questions, Ampio remains silent. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein